Companies · AI / ML

Clinigence Holdings, Inc.

HOUSTON · AI / ML · refined from filed group “Other Health Care · https://clinigencehealth.com/

Diligence memoA one-page analyst read on Clinigence Holdings, Inc. — recommendation, valuation, rhythm, risks.
$2.5B
Total raised · real
8
Rounds
0.0×
Latest step-up
Top 1%
Sector rank · raised
Growth/Late
Latest stage · inferred · Sat Sep 30 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Clinigence Holdings, Inc. looks under-valued against its niche peers and is at-risk on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the ai/ml sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.01× the median modeled value of Growth/Late AI / ML companies in 2022–2024 (5 peers) — value vs value, same stage and era.
At-risk
  • Last raise 2.8 yr ago; this sector typically re-raises about every 11 months.
  • Past due for a raise versus sector cadence — watch for distress or a bridge.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Clinigence Holdings, Inc. behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
8.0 yr record
Peak capital year was 2022 with $2.4B across 1 filings.
Market position
ahead of 100% of AI / ML peers
Capital scale is ahead of 100% of AI / ML peers; modeled value is above 86% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Some evidence
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • Capital program peaked in 2022: $2.4B across 1 filings.
  • Largest single filing was $2.4B on 2022-04-01.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in AI / ML

Clinigence Holdings, Inc. is one of 2067 AI / ML companies tracked from HOUSTON. By capital raised it ranks among the largest (ahead of 100% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%

operates a technology-led product inferred from public copy

Grounded in: “You are a venture analyst

Discover the advanced analytics-driven solution for payers and provider organizations - Clinigence Health software.

Discover the advanced analytics-driven solution for payers and provider organizations - Clinigence Health software. Discover the advanced business intelligent software solution that turns your data into useful insights for the health care ecosystem to enhance value-based care through generative AI. Developed with the success of the end user in mind. The QMX® provides: Discover how Clinigence Health Makes a Difference Today

ai/ml
Find Clinigence Health online

Trades publicly as Clinigence Health.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
13
Investors (latest)
2023-09-30
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$25.0B$50.0B$75.0B$100.0BSeries A · 2018-07-01 Raised $8.8M (real) Modeled valuation $316M (est)Series A2018Series A · 2018-10-24 Raised $3.1M (real) Modeled valuation $113M (est)Series A2018Series B · 2019-03-21 Raised $16M (real) Modeled valuation $623M (est)Series B2019Series B · 2019-10-24 Raised $2.3M (real) Modeled valuation $93M (est)Series B2019Series B · 2019-10-29 Raised $24M (real) Modeled valuation $972M (est)Series B2019Series B · 2019-10-29 Raised $24M (real) Modeled valuation $972M (est)Series B2019Series B · 2021-03-02 Raised $32M (real) Modeled valuation $974M (est)Series B2021Series B · 2021-05-14 Raised $11M (real) Modeled valuation $319M (est)Series B2021Seed · 2021-05-14 Raised $1.9M (real) Modeled valuation $54M (est)Seed2021Growth/Late · 2022-04-01 Raised $2.4B (real) Modeled valuation $63.6B (est)Growth/Late2022Growth/Late · 2023-09-30 Raised $3.1M (real) Modeled valuation $56M (est)Growth/Late2023Cumulative $2.5B

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$8.8M · 2018
Series A extension$3.1M · 2018
Series B$15.7M · 2019
Series B extension$2.3M · 2019
Series B extension$24.5M · 2019
Series B extension$24.5M · 2019
Series B extension$32.0M · 2021
Series B extension$11.3M · 2021
Bridge · Series B-stage$1.9M · 2021smaller follow-on
Growth/Late$2.4B · 2022no Series C / Series D+ on file
Growth/Late extension$3.1M · 2023

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Series C, Series D+ — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 57%.

Modeled valuation trajectory
$56.0M
Base estimate est.
$23.6M
Conservative case
$76.4M
Upside case
$30.9M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Growth/Latea round over $400M). Valuation is modeled from stage benchmarks scaled by the ai/ml sector profile. Directional, not a quoted figure.

Series A · modeled $316.2M · 2018-07-012018Series A · modeled $112.6M · 2018-10-24Series B · modeled $622.6M · 2019-03-21Series B · modeled $93.0M · 2019-10-24Series B · modeled $971.6M · 2019-10-29Series B · modeled $971.6M · 2019-10-29Series B · modeled $974.4M · 2021-03-02Series B · modeled $318.9M · 2021-05-14Seed · modeled $54.4M · 2021-05-14Growth/Late · modeled $63.6B · 2022-04-01Growth/Late · modeled $56.0M · 2023-09-302023
Model inputs · modeled:benchmark-stage-stepup-v1
10%
Dilution assumption
Implied ownership sold in the financing.
88%
Survival probability
76% low · 95% high
1.30×/yr
Annual markup
1.42×/yr upside case
2.8 yr
Elapsed time used
2.8 yr actual, capped for stale marks
ai/ml
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
6 mo
Avg between rounds
$469.3M/yr
Capital velocity
8.0 yr
On record since
2018
First round
11
Rounds on file
How it compares to the market

Benchmarked against 2067 companies in AI / ML. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 521× above median
This company$2.5B
Sector median$4.7M
Latest round — vs other Growth/Late rounds in sector (real $, this stage) 0.0× of median
This company$3.1M
Sector median$575.3M
Modeled value — vs sector median (estimate, all stages) 2.0× above median
This company$56.0M
Sector median$27.9M

Raised more than 100% of sector peers (real $). Modeled value above 86% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Growth/Late) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #4 of 5.

This companyCohort peer
$10.0M$100.0M$1.0B$10.0B$100.0B$100K$1.0M$10.0M$100.0M$1.0B$10.0BCapital raised (log)CoreWeave, Inc. · Growth/Late Raised $1.2B · modeled $17.7B (est)SMG Aggregator, LLC · Growth/Late Raised $601.7M · modeled $10.9B (est)Figma, Inc. · Growth/Late Raised $715.5M · modeled $6.4B (est)Envisionit Deep AI · Growth/Late Raised $1.6M · modeled $34.9M (est)Clinigence Holdings, Inc. (this company) Raised $2.5B · modeled $56.0M (est)Clinigence Holdings, Inc.
CompanyStageRaised · realValue · estvs peer med.
CoreWeave, Inc.Growth/Late$1.2B$17.7B2.76×
SMG Aggregator, LLCGrowth/Late$601.7M$10.9B1.70×
Figma, Inc.Growth/Late$715.5M$6.4B1.00×
Clinigence Holdings, Inc. this companyGrowth/Late$2.5B$56.0M0.01×
Envisionit Deep AIGrowth/Late$1.6M$34.9M0.01×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$8.8M2018-07-01$39.8M$316.2M90%
Series A$3.1M2018-10-24$14.2M$112.6M90%
Series B$15.7M2019-03-21$87.2M$622.6M90%
Series B$2.3M2019-10-24$13.0M$93.0M90%
Series B$24.5M2019-10-29$136.1M$971.6M90%
Series B$24.5M2019-10-29$136.1M$971.6M90%
Series B$32.0M2021-03-02$177.6M$974.4M90%
Series B$11.3M2021-05-14$62.9M$318.9M90%
Seed$1.9M2021-05-14$9.6M$54.4M90%
Growth/Late$2.4B2022-04-01$23.7B$63.6B90%
Growth/Late$3.1M2023-09-30$30.9M$56.0M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$8.8M2018-07-01
    • First recorded raise — entered as Series A.
  2. Series A$3.1M2018-10-24
    • Came back fast: 4 mo vs the ~11 mo sector norm.
    • Round 2.8× smaller than the prior — bridge or down round.
    • 21 investors on this round.
  3. Series B$15.7M2019-03-21
    • Came back fast: 5 mo vs the ~11 mo sector norm.
    • Round 5.0× larger than the prior — scaling up.
    • 31 investors on this round.
  4. Series B$2.3M2019-10-24
    • Raised 7 mo later, in step with the ~11 mo sector norm.
    • Round 6.7× smaller than the prior — bridge or down round.
    • 17 investors on this round.
  5. Series B$24.5M2019-10-29
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 10.4× larger than the prior — scaling up.
    • 114 investors on this round.
  6. Series B$24.5M2019-10-29
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 114 investors on this round.
  7. Series B$32.0M2021-03-02
    • Raised 16 mo later, in step with the ~11 mo sector norm.
    • Round 1.3× larger than the prior — scaling up.
    • 58 investors on this round.
  8. Series B$11.3M2021-05-14
    • Came back fast: 2 mo vs the ~11 mo sector norm.
    • Round 2.8× smaller than the prior — bridge or down round.
    • 73 investors on this round.
  9. Seed$1.9M2021-05-14
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 5.9× smaller than the prior — bridge or down round.
    • 12 investors on this round.
  10. Growth/Late$2.4B2022-04-01
    • Raised 11 mo later, in step with the ~11 mo sector norm.
    • Round 1231.8× larger than the prior — scaling up.
    • 123 investors on this round.
  11. Growth/Late$3.1M2023-09-30
    • Raised again after 18 mo — slower than the ~11 mo sector norm.
    • Round 767.4× smaller than the prior — bridge or down round.
    • 13 investors on this round.
Intelligence
2024 ~Q2
Modeled next raise · ~6mo cadence
$3.1M
Modeled next size est.range $3.1M$4.9M
0.0×
Last step-up
$469.3M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
MICHAEL CHANG12 other2022-04
Matthew Young6 other2022-04
Mihir Shah6 other2018-10
Michael Bowen5 other2021-03
Warren Hosseinion3 other2018-10
Elisa Luqman2 other2021-03
Warren Hosseinionn2 other2023-09
John Waters1 other2019-10
Lawrence Schimmel1 other2018-10
Mark Fawcett1 other2021-05
Martin Breslin1 other2018-10
Michael Reed1 other2022-04
Richard Chan1 other2021-03
Andrew Barnett2021-03
Brandon Sims2021-05
Charles Kandzierski2018-10
Cheryl Grenas2022-04
Danniel Stites2023-09
David Martin Meiri2019-10
David Meiri2018-10
Denise Pufal2022-04
Elisa Martin Luqman2019-10
Fred Sternberg2021-03
Hosseinion Warren2021-05
Registry & provenance

Clinigence Holdings, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1479681
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Apollo Medical Holdings, Inc.HealthtechSeries D+$312.8M$11.2Mnetwork3 shared operators
Vesicor Therapeutics, Inc.BiotechnologyPre-Seed$715K$2.4Mnetwork3 shared operators
Hera Topco, Inc.OtherGrowth/Late$462.7M$7.2Bnetwork1 shared operator · same stage
Cardio Diagnostics Inc.BiotechnologySeries A$13.2M$94.2Mnetwork2 shared operators
Qualmetrix, Inc.Other Health CareSeries A$6.1M$100.9Mnetwork2 shared operators
Envisionit Deep AIAI / MLGrowth/Late$1.6M$34.9Msame sector · same stage
Cardio Diagnostics Holdings, Inc.BiotechnologyPre-Seed$1.0M$6.0Mnetwork2 shared operators
Tiny Ltd.AI / MLSeries C$73.8M$14.5Msame sector
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
DOC.AI IncAI / MLSeed$101.0M79%
ThinkBio.Ai, IncAI / MLPre-Seed$4.5M77%
Cygnus-AI Inc.AI / MLPre-Seed$29.2M77%
Clarion
The AI communication layer for healthcare
Healthtech77%
Neural Analytics, Inc.AI / MLSeries B$258.0M77%
Cohort Intelligence CorpAI / MLSeries A$342.0M76%
Lilia Ai, Inc.AI / MLSeed$4.6M76%
Healwell AI Inc.AI / MLSeed$9.9M76%
Frequently asked
How much funding has Clinigence Holdings, Inc. raised?
Clinigence Holdings, Inc. has raised approximately $2.5B in disclosed capital across 8 recorded financing rounds, aggregated from public filings.
What is Clinigence Holdings, Inc.'s estimated valuation?
Provath's modeled valuation for Clinigence Holdings, Inc. is approximately $56.0M (modeled range $23.6M–$76.4M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Clinigence Holdings, Inc. at?
Clinigence Holdings, Inc.'s latest modeled financing stage is Growth/Late. Its most recent recorded round closed around Sat Sep 30.
What does Clinigence Holdings, Inc. do and where is it based?
Clinigence Holdings, Inc. operates in the AI / ML sector, based in HOUSTON. Discover the advanced analytics-driven solution for payers and provider organizations - Clinigence Health software.
Explore related

See where Clinigence Holdings, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Clinigence Holdings, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.